International Workshop of Scleroderma Research

July 30 – August 3, 2022

Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD

Contact us to get more information about the company and the compelling nonclinical studies results that supports moving the program into human clinical trials.

QUICK CONTACT

USEFUL LINKS